DeepMed Research

NOVACEA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

Phase 2

Suspended

Conditions: Pancreatic Cancer

Interventions: Drug: Placebo + gemcitabine
Drug: placebo + gemcitabine + erlotinib
Drug: calcitriol + gemcitabine
Drug: calcitriol + gemcitabine + erlotinib

First Posted Date: 2007-09-28

Last Posted Date: 2007-11-06

Lead Sponsor: Novacea

Target Recruit Count: 132

Registration Number: NCT00536770

Locations: 🇺🇸
Novacea Investigational Site, Nashville, Tennessee, United States

AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Conditions: Glioblastoma Multiforme

First Posted Date: 2006-11-01

Last Posted Date: 2007-05-30

Lead Sponsor: Novacea

Target Recruit Count: 60

Registration Number: NCT00394628

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Henry Ford Health Systems, Detroit, Michigan, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 2 locations

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Phase 2

Conditions: Androgen Independent Prostate Cancer (AIPC)
Non Small Cell Lung Cancer (NSCLC)

First Posted Date: 2006-02-02

Last Posted Date: 2006-05-31

Lead Sponsor: Novacea

Target Recruit Count: 25

Registration Number: NCT00285675

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
University of Pittsburgh,William Copper Ambulatory Care, Pavillion Hellman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Kaiser Permanente Medical Group, Northern California, Vallejo, California, United States

and more 10 locations

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Phase 3

Terminated

Conditions: Prostate Cancer

First Posted Date: 2006-01-09

Last Posted Date: 2007-11-06

Lead Sponsor: Novacea

Target Recruit Count: 1200

Registration Number: NCT00273338

Locations: 🇺🇸
UCLA department of Urology, Los Angeles, California, United States
🇺🇸
Hematology Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 209 locations

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

Phase 1

Conditions: Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia

First Posted Date: 2005-04-27

Last Posted Date: 2007-05-07

Lead Sponsor: Novacea

Target Recruit Count: 55

Registration Number: NCT00109356

Locations: 🇺🇸
Weill Medical College of Cornell University/ New York Presbyterian Hospital, New York, New York, United States

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Conditions: Solid Malignancies
Non-Hodgkin's Lymphoma

First Posted Date: 2004-09-06

Last Posted Date: 2006-11-02

Lead Sponsor: Novacea

Target Recruit Count: 45

Registration Number: NCT00090727

Locations: 🇺🇸
Weiler Hospital of Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸
Cancer Therapy & Research Center / Institute for Drug Development, San Antonio, Texas, United States

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-08-08

Last Posted Date: 2007-05-07

Lead Sponsor: Novacea

Target Recruit Count: 80

Registration Number: NCT00066885

Locations: 🇺🇸
New York Oncology Hematology, P.C. - Albany Regional Cancer Center, Albany, New York, United States
🇺🇸
Cancer Care Associates, Tulsa, Oklahoma, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

and more 8 locations

Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Phase 2

Conditions: Myelodysplastic Syndrome

First Posted Date: 2003-04-01

Last Posted Date: 2006-11-01

Lead Sponsor: Novacea

Target Recruit Count: 46

Registration Number: NCT00057031

Locations: 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
Boston Baskin Cancer Group, Memphis, Tennessee, United States
🇺🇸
James A. Haley Veterans Hospital, Tampa, Florida, United States

and more 7 locations

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2003-02-25

Last Posted Date: 2009-07-28

Lead Sponsor: Novacea

Target Recruit Count: 60

Registration Number: NCT00055263

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere

Phase 2

Conditions: Prostate Cancer

First Posted Date: 2002-08-13

Last Posted Date: 2009-03-12

Lead Sponsor: Novacea

Target Recruit Count: 250

Registration Number: NCT00043576

Locations: 🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸
Texas Oncology, P.A., Dallas, Texas, United States
🇺🇸
Kaiser- Northern California, Vallejo, California, United States

and more 59 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy